Gonzalez-Rodriguez E, et al., Immune checkpoint inhibitors: Review and management of endocrine adverse events. Oncologist 2016; 21:804-16.Gonzalez-Rodriguez E, Rodriguez-Abreu D (2016) Immune checkpoint inhibitors: Review and management of endo- crine adverse events. Oncologist 21: 804-816....
The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer treatment, enabling the possibility of long-term survival in patients with metastatic disease, and providing new therapeutic indications in earlier-stage settings. As such, characterizing the long-term implications ...
Results The role of immune checkpoint inhibitors has been investigated both for the treatment of viral hepatitis and primary liver cancer. Hepatocellular carcinoma and chronic hepatitis B show the greatest potential for treatment with these drugs in the near future. However, immune‐related adverse ...
et al. Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis. JCO Precis Oncol. 2017;1:1–15.
Immune checkpoint inhibitors (CPIs) are a relatively newly licenced cancer treatment, which make a once previously untreatable disease now amenable to a potential cure. Combination regimens of anti-CTLA4 and anti-PD-1 show enhanced efficacy but are prone
2023 Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular CarcinomaA Systematic Review and Meta-Analysis Enrui Xie, MD1; Yee Hui Yeo, MD2; Bernhard Scheiner, MD, PhD3,4; et al Yue Zhang, MD1,5; Atsushi Hiraoka, MD, PhD6; Xinxing Tantai, MD7; Petros Fessas, MD3...
With immune checkpoint inhibitors (ICIs) becoming the mainstay of treatment for many cancers, managing their immune-related adverse events (irAEs) has become an important part of oncological care. This Review covers the clinical presentation of irAEs and
Immune Checkpoint Inhibitors for Patients with Advanced Non-Small-Cell Lung Cancer: A Systematic Review. Clin. Lung Cancer 2017, 18, 444–459.e1. [Google Scholar] [CrossRef] [PubMed] Khanna, P.; Blais, N.; Gaudreau, P.-O.; Corrales-Rodriguez, L. Immunotherapy Comes of Age in Lung...
[1]. Immune checkpoint inhibitors are associated with a range of immune related adverse events (iRAEs), including gastrointestinal, dermatologic, rheumatic, pulmonary, renal, hepatic and cardiac [2]. In this review, we will focus on cardiotoxicities of immune checkpoint inhibitor therapy, including...
Review Open Access Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer Yunchang Li, ... Chuan Xu How to Cite Li Y, Hu L, Peng X, Xu H, Tang B, Xu C. Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer. Cancer Drug Re...